EyePoint Inc. (EYPT) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, EYPT scores 26 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 6 / 20 (ROIC -35%; FCF yield 0%), Whale 13F Flow scores 3 / 20, Insider Conviction scores 3 / 20, Macro Regime Fit scores 6 / 20 (Beta 1.0), and Forensic Balance Sheet scores 8 / 20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). For a prospective investor, the weakest pillars are institutional and insider conviction, which signal little supportive positioning, and the cash engine, which shows negative returns on capital and no free-cash-flow yield. The balance sheet pillar is comparatively less weak but still scores low on the Piotroski test. The rating frames the stock as a forensic-risk name; any upside thesis would need to rest on a catalyst strong enough to overcome these pillar readings, and the source data does not establish that catalyst.

Per the SEC financials, the company reported losses in each period shown, with FY 2025 net income of $-232.0M. Per the Roarable RQD rating and market data, operating margin and net margin are each -60%, gross margin is 0%, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, per the Roarable RQD rating, with Debt/Equity of 0.5. The reported cash balance of $101.8M for FY 2025 compares with a market capitalization of $32.8M per the market data.

The news wire contains six items, all tagged to EYPT. Headlines reference a Duravyu trial setback and a fair value cut, a stock decline of 82% after a key eye drug failure with staff cuts, a late-stage trial setback, layoffs, a collapse of over 80%, and a Stock Titan report of five parties disclaiming ownership of shares held by Managed Funds. Of these, four are tagged RED / RISK WATCH and two are tagged YELLOW / MARKET WIRE. The source data does not provide further detail on the content of these reports. Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals.

• What products or technologies generate EyePoint's $31.4M of FY 2025 revenue, and who are its customers?
• What is the status and timeline of the Duravyu program referenced in the news wire, and what did the trial setback specifically show?
• What is the company's cash runway given $101.8M of reported cash against FY 2025 free cash flow of $-243.4M?
• What drove the reported staff reductions, and what is the expected effect on operating costs?
• Why is EPS, debt, and forward valuation data absent from the source, and what does the Managed Funds disclaimer in the holder filing relate to?